Koneqia Therapeutics is a clinical-stage biotechnology company focused on developing novel therapeutics for neurodegenerative diseases, with a primary emphasis on Alzheimer's disease. The company leverages its proprietary brain access platform to enable delivery of therapeutic molecules across the blood-brain barrier (BBB)[1].
Founded in 2022 and headquartered in San Francisco, California, Koneqia aims to address the critical challenge of CNS drug delivery that has hindered the development of effective treatments for Alzheimer's and other neurological disorders.
| Drug | Mechanism | Stage | Status |
|---|---|---|---|
| KQ-001 | Brain-penetrant TREM2 modulator | Phase 1 | Recruiting |
| KQ-002 | ApoE4 modifier | Preclinical | IND-enabling |
| KQ-003 | Synaptic protector | Discovery | Research |
Koneqia's proprietary BBB platform enables:
The platform addresses a fundamental challenge in CNS drug development: the BBB prevents approximately 98% of small molecule drugs and virtually all large molecule therapeutics from reaching the brain in therapeutic concentrations[2].
KQ-001 is a small molecule TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) modulator designed to:
This approach differs from antibody-based TREM2 agonists by offering potential for oral dosing and improved brain penetration.
TREM2 is a receptor expressed primarily on microglia in the brain. Genetic variants in the TREM2 gene significantly increase AD risk:
TREM2 signaling regulates microglial:
Koneqia's approach aims to develop small molecules that enhance TREM2 signaling, potentially improving microglial function in AD patients[3].
The company's ApoE4 modifier program targets apolipoprotein E4, the strongest genetic risk factor for late-onset AD:
| Company | Drug | Mechanism | Stage |
|---|---|---|---|
| Koneqia | KQ-001 | TREM2 modulator | Phase 1 |
| Denali | DNL622 | TREM2 agonist | Phase 1 |
| Alector | AL002 | TREM2 agonist | Phase 2 |
| AbbVie | ABBV-916 | TREM2 antibody | Preclinical |